SecBot SecBot
PRESS-RELEASE ·Filed Nov 2, 2026

URGN

UroGen Pharma Ltd.
NEUTRAL
Impact 4/10
Horizonmonths Processed14d 18h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

This is a very early clinical milestone with no efficacy data. The absence of RTGel in the current formulation means the Phase 1 results may not reflect the potential of the RTGel-formulated version. Monitor for safety and tolerability readouts and any updates on the RTGel formulation studies.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$34.36
T+0 close · Nov 2, 2026 · via day close
Latest settled
−23.43%
T+5 · $26.31 · next T+20 in 14d
Vs SPY
−23.51%
α at T+5
Latest observation
−24.45%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $34.36entry
  2. T+1 · 14d ago +0.12%α −0.18% · $34.40
  3. T+5 · 8d ago −23.43%α −23.51% · $26.31
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UroGen Pharma announced the first patient dosed in a Phase 1 trial of UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial evaluates safety, tolerability, and pharmacokinetics of intravesical administration. This is an early-stage clinical milestone with no efficacy data yet, and the formulation being tested does not use UroGen's proprietary RTGel technology.

Key Facts

  • First patient dosed in Phase 1, open-label, dose-escalation trial of UGN-501 for NMIBC.
  • UGN-501 is an investigational next-generation oncolytic virus designed for direct tumor cell destruction and anti-tumor immune activation.
  • The Phase 1 trial will determine the recommended Phase 2 dose in adults with recurrent NMIBC (high-grade Ta/T1, CIS, or low-grade Ta/T1).
  • The formulation in this Phase 1 trial is aqueous and does not contain UroGen's proprietary RTGel technology.
  • Parallel nonclinical studies are exploring UGN-501 formulated with RTGel.
  • Trial design: six once-weekly instillations over 12 weeks; maintenance for responders (three weekly instillations quarterly from month 3 to month 12).

Financial Impact

No financial data disclosed; early clinical milestone with no revenue impact expected for years.

Risk Factors

  • Phase 1 trial is early-stage; safety or efficacy issues could halt development.
  • The current formulation does not use RTGel, which may limit therapeutic potential versus the RTGel version.
  • NMIBC is a competitive space with multiple approved therapies; UGN-501 must differentiate to succeed.
  • Forward-looking statements carry risks of clinical failure, regulatory hurdles, and need for additional capital.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3393063

Track record

16 reports on URGN

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +54.89% at T+60 after the Mar 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $25.90 Now $28.10 +8.49% settles Nov 23
  2. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  3. Nov 4, 202612d ago Press Release Bearish 6/10 Entry $28.74 to $26.10 Now $28.10 +2.23% ▲ +9.19% +8.27% vs SPY
  4. Nov 2, 202614d ago Press Release Neutral 4/10 Viewing Entry $34.36 to $26.31 Now $28.10 −18.22% ▼ −23.43% −23.51% vs SPY
  5. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $33.75 to $28.74 Now $28.10 −16.74% ▼ −14.84% −14.13% vs SPY
  6. Oct 19, 202628d ago Press Release Bullish 6/10 Entry $34.15 to $34.23 Now $28.10 −17.72% ▲ +0.23% +0.38% vs SPY
  7. Oct 9, 20265w ago 144 Neutral 2/10 Entry $36.83 to $34.56 Now $28.10 −23.70% ▼ −6.16% −4.20% vs SPY
  8. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $45.00 to $43.04 Now $28.10 −37.56% ▼ −4.36% −4.02% vs SPY
  9. Aug 20, 202612w ago 8-K Neutral 4/10 Entry $46.80 to $45.50 Now $28.10 −39.96% ▼ −2.78% −3.89% vs SPY
  10. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $46.43 to $49.00 Now $28.10 −39.48% ▲ +5.54% +5.18% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026